The global influenza vaccine market value was USD 5.9 billion in 2023, driven by increased awareness about the health risks associated with influenza across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2024-2032 to achieve a value of USD 11.1 billion by 2032.
An influenza vaccine, variously known as a flu vaccine, is a vaccine that provides protection against the various strains of influenza. As influenza is most prevalent in the monsoon season, the vaccine prevents the risk of influenza-related complications like ear infections and bacterial pneumonia. An influenza vaccine is one of the most crucial vaccinations to bolster the quality of life.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increasing awareness regarding the benefits of influenza to prevent adverse side effects of influenza infection is augmenting the market growth. Various governments bodies such as the Food and Drug Administration (FDA) of the United States and the European Commission, among others, are increasingly authorising effective influenza vaccines. This, in turn, is preventing the spread of the disease and increasing the healthcare quality, hence driving the market growth. Furthermore, the growing demand for innovative zoonotic influenza vaccines to prevent the potential spread of influenza from animals is providing impetus to the growth of the market.
The market for influenza vaccine is being aided by the growing demand for influenza vaccines in developing countries due to the high prevalence of influenza-related deaths. Moreover, various governments are increasingly providing influenza vaccines for children to prevent the surge of complicated health issues. As the monsoon season in developing countries results in a surge in cases of influenza, routine administration of vaccines against the disease is recommended, which is significantly contributing to the growth of the market. In addition, the initiation of various research activities by governments to develop a vaccine that provides protection against various strains of the influenza virus is predicted to drive the market growth in the forecast period.
The market can be segmented on the basis of vaccine type, technology, route of administration, age group, distribution channel, and major region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Vaccine Type
Market Breakup by Technology
Market Breakup by Route of Administration
Market by Age Group
Market Breakup by Distribution Channel
Market Breakup by Region
The market growth is being aided by the growing adoption of cold-adapted influenza virus vaccines to boost the efficacy and safety of vaccination. Such vaccines do not result in any adverse side effects, due to which they are increasingly preferred for children. As cold-adapted vaccines can be administered through a nasal spray, they are ideal for the trypanophobia population, which is bolstering the growth of the market. Moreover, the increasing approvals of cold-adapted influenza vaccines by healthcare bodies are driving the growth of the influenza vaccine market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Advancements in vaccination technology are leading to the development of influenza vaccines from negative-strand RNA virus, which is predicted to propel the growth of the market. Moreover, the development of effective mRNA vaccines against SARS-CoV-2 during the COVID-19 crisis is leading to a surge in research activities to develop efficient mRNA influenza vaccines, which is expected to significantly contribute to the market growth.
In addition, various studies and clinical trials are initiated by leading companies to determine the benefits, immunogenicity, and safety of the mRNA influenza vaccine.
The report presents a detailed analysis of the following key players in the global influenza vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Vaccine Type||
|Breakup by Technology||
|Breakup by Age Group||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Influenza Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Influenza Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Influenza Epidemiology (2016-2031)
5.3 Europe Influenza Epidemiology (2016-2031)
5.4 Asia-Pacific Influenza Epidemiology (2016-2031)
5.5 Latin America Influenza Epidemiology (2016-2031)
5.6 Middle East & Africa Influenza Epidemiology (2016-2031)
6 Global Influenza Vaccine Market Overview
6.1 Global Influenza Vaccine Market Historical Value (2017-2023)
6.2 Global Influenza Vaccine Market Forecast Value (2024-2032)
7 Global Influenza Vaccine Market Landscape
7.1 Global Influenza Vaccine Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Influenza Vaccine Product Landscape
7.2.1 Analysis by Vaccine Type
7.2.2 Analysis by Technology
7.2.3 Analysis by Age Group
8 Influenza Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Influenza Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Influenza Vaccine Market Segmentation
11.1 Global Influenza Vaccine Market by Vaccine Type
11.1.1 Market Overview
11.2 Global Influenza Vaccine Market by Technology
11.2.1 Market Overview
11.2.2 Egg Based
11.2.3 Cell Based
11.3 Global Influenza Vaccine Market by Age Group
11.3.1 Market Overview
11.4 Global Influenza Vaccine Market by Route of Administration
11.4.1 Market Overview
11.4.3 Nasal Spray
11.5 Global Influenza Vaccine Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Government and Institution Supply
11.6 Global Influenza Vaccine Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Influenza Vaccine Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Influenza Vaccine Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Influenza Vaccine Market
14.1 Market Share by Country
15 Latin America Influenza Vaccine Market
15.1 Market Share by Country
16 Middle East and Africa Influenza Vaccine Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
23 Supplier Landscape
23.1 AstraZeneca plc
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Biodiem Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 CSL Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Emergent BioSolutions Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 F. Hoffmann-La Roche AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Gamma Vaccines Pty Ltd
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 GlaxoSmithKline Plc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Merck and Co., Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Pfizer Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Sanofi S.A.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
24 Global Influenza Vaccine Market- Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The influenza vaccine market was valued at USD 5.9 billion in 2023.
The market is expected to grow at a CAGR of 7.3% from 2024 to 2032 to reach a value of USD 11.1 billion by 2032.
The market is being aided by the rising awareness regarding the importance of influenza vaccines, the growing authorisation of vaccines, and the high prevalence of influenza-related issues in developing countries.
The market is expected to be propelled by the growing adoption of cold-adapted influenza vaccines, advancements in vaccines technology, and the initiation of clinical trials for the development of new and innovative influenza vaccines.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of vaccine include quadrivalent and trivalent.
The technologies in the market include egg-based and cell-based, among others.
The routes of administration include injection and nasal spray.
The age groups can be categorized into paediatric and adult.
The distribution channels can be categorised into hospitals, retail pharmacies, and government suppliers, among others.
The key players in the market include AstraZeneca plc, Biodiem Limited, CSL Limited, Emergent BioSolutions Inc., Gamma Vaccines Pty Ltd, GlaxoSmithKline Plc., Merck and Co., Inc., Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche AG.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.